Healthcare Industry News: IRIDEX
News Release - April 3, 2008
OptiMedica Names New Vice Presidents of Marketing and OperationsSANTA CLARA, Calif.--(HSMN NewsFeed)--OptiMedica Corp., a global ophthalmic device company, has appointed Robert P. Eno and Robert A. Haddad to the new positions of vice president of marketing and vice president of operations, respectively. In their new roles, Eno and Haddad are expected to help accelerate the global commercialization of OptiMedica’s PASCAL® (Pattern SCAn Laser) Photocoagulator, a fully integrated pattern scan laser designed to treat a variety of retinal diseases.
“Eno and Haddad join OptiMedica’s leadership team at a pivotal time for growth and expansion,” said Mark J. Forchette, president and chief executive officer of OptiMedica. “With their proven experience and talent, we expect each to play a significant role in driving rapid worldwide acceptance and market adoption of our PASCAL technology.”
Eno joins OptiMedica from emerging medical device company NeoGuide Systems Inc., where he served as vice president of marketing. Prior to NeoGuide, he was vice president of marketing and sales for Avantec Vascular Corporation. Eno also spent six years at Guidant Corporation’s Vascular Intervention Division, where he held various roles of increasing responsibility in marketing, product management and strategic planning.
Prior to OptiMedica, Haddad was vice president of international operations and business development at Elkin Medical Systems Inc. He was previously co-founder and chief operating officer of Translucent Photonics. Haddad also held various vice president- and director-level positions in product development and operations at companies including Sunrise Technologies International, IRIDEX Corporation, Coherent Inc. and Abekas Video Systems.
“I believe that OptiMedica’s PASCAL technology has the potential to make a profound, positive impact on the field of ophthalmology as well as patient quality of life. I look forward to helping drive the kind of company growth that will make PASCAL available to significant numbers of ophthalmologists and patients worldwide,” said Eno.
Added Haddad, “With its elegant core technology, tremendous short- and long-term market potential and excellent leadership team and financing in place, OptiMedica is clearly positioned for great success. I see my role as helping to execute against an already well conceived plan.”
OptiMedica Corp. is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. OptiMedica holds the exclusive license to the PASCAL® (PAttern SCAn Laser) method of photocoagulation and its associated technologies, which are approved by the U.S. Food and Drug Administration for treatment of a variety of retinal conditions. Clinical experience with PASCAL has demonstrated unmatched precision, efficiency and patient comfort. Founded in 2004, the company is headquartered in Santa Clara, Calif., with international offices in Singapore. OptiMedica is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures and DAG Ventures. For more information, please visit www.optimedica.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.